Voyager Therapeutics Inc

Voyager Therapeutics plans to develop life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, Huntington’s disease, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau and alpha-synuclein protein in the brain. Voyager’s mission is to develop and deliver life-changing therapies to people around the world living with severe neurological diseases. This begins with a commitment to discovery, research, development and manufacturing, and extends to our engagement with patients, healthcare providers, caregivers and advocacy organizations.